Introduction
============

Hypnotics such as short-acting benzodiazepines and the newer non-benzodiazepines zolpidem and zopiclone ("Z-drugs") are the most common pharmacological treatment for insomnia \[[@R1]\], \[[@R2]\]. Although there is no evidence of differences in clinical effectiveness and safety between these substance groups \[[@R3]\], \[[@R4]\], Z-drugs are increasingly prescribed since their introduction in the early 1990s while the use of benzodiazepine hypnotics decreased \[[@R2]\], \[[@R5]\], \[[@R6]\]. A reason for this trend seems to be that general practitioners (GPs) attribute Z-drugs with greater benefits and fewer side effects compared to benzodiazepines \[[@R1]\], \[[@R7]\]. GPs further perceived that Z-drugs were safer for elder patients, which also contradicts the current evidence. Benefits of hypnotics for older persons are modest at best and are outweighed by the increased risks \[[@R8]\].

Community pharmacists (CPs) have an important role in providing information on medicines. Their own profession as well as a large majority of physicians want pharmacists' involvement in counselling patients about adverse effects \[[@R9]\], a result that has also been found for hypnotics \[[@R10]\]. Pharmacists are experts on drugs and might have a better knowledge on adverse effects. This hypothesis is supported by a comparison of therapeutic knowledge of GPs and CPs on simple analgesics \[[@R11]\] but not for opioids in another study \[[@R12]\]. However, no further evidence is available on this topic.

The aim of this study was to compare perceptions on benefits and harms of benzodiazepines and Z-drugs between German GPs and CPs.

Patients, materials and methods
===============================

Design, participants and measures
---------------------------------

In Germany, about 55,000 GPs are working in the outpatient sector and there are about 22,000 community pharmacies. Two questionnaire surveys were mailed to 1,350 and 600 randomly selected GPs and owners of community pharmacies, respectively. The surveys were conducted between May and November 2012 and the designs were quite comparable. Several strategies shown by a Cochrane review to increase response to postal questionnaires were applied \[[@R13]\]. Those include pre-notification, a short questionnaire, follow-up contact, providing a second copy of the questionnaire at follow-up, personalised postcards and letters, hand-written signatures, and academic origin of the study. A postcard announcement was sent one week before the two-sided questionnaire including a pre-addressed return envelope was mailed out. Three weeks later, a reminder including another copy of the questionnaire and a pre-addressed return envelope were sent to all non-responders. No further actions were taken and no financial incentives were provided.

Both questionnaires included two sections concerning the perceptions of benefits and harms of benzodiazepines and Z-drugs for the treatment of insomnia. In order to do so, the same questions consisting of 12 items were asked on both benzodiazepines and Z-drugs. Each of these items was rated on a five-point Likert scale. For instance, answers on participants' estimates on the frequencies of side effect of these hypnotics ranged from "never/very rarely" to "very often/always". These items were adopted from a British study on the same topic \[[@R7]\].

Results of the GP survey with a focus on the comparison of benzodiazepines and Z-drugs have already been published elsewhere \[[@R1]\]. The questionnaire is available online (<http://www.smw.ch/fileadmin/smw/pdf/SMW-13745-Appendix.pdf>).

Statistical analysis
--------------------

Baseline characteristics are presented as percentages or means with standard deviation. The non parametric Wilcoxon signed rank test was used for the comparison of perceptions between GPs and CPs. Responses on the five-point Likert scales are presented within three categories. Due to multiple testing, only p-values ≤0.01 were considered statistically significant.

All analyses were performed with SAS for Windows version 9.2 (SAS Institute Inc., Cary, NC).

Results
=======

Baseline characteristics
------------------------

Out of 1,350 questionnaires sent out to GPs, 458 were returned (response 33.9%). Mean age of the respondents was 53.3 years (SD: 8.7) and 40.6% of them were female. On average, they were 16.3 years in practice and nearly half of them work in single-handed practices (51.9%).

Of the 600 pharmacist surveys, 202 were received (response 33.7%). The mean age of CPs was 48.8 years (SD: 11.0). With 59.2% the proportion of females was higher compared to the physicians. On average, 2.5 pharmacists work in the pharmacies of the respondents.

Comparison of perceptions on benzodiazepines and Z-drugs
--------------------------------------------------------

Attitudes of GPs and CPs on benefits and side effects of benzodiazepines and Z-drugs are summarized in Table 1 [(Tab. 1)](#T1){ref-type="fig"}. Perceptions on benefits of benzodiazepines between GPs and CPs were not different for 3 of the 5 items. CPs rated these drugs to be more effective in terms of reduced night-time waking and increased total sleep time. On the other hand, no statistically significant differences between GPs and CPs were found for 2 out of 5 items on benefits of Z-drugs. GPs perceived that Z-drugs were significantly more effective in terms of feelings of being rested on waking and improved daytime functioning, but CPs believed that the effect on reduced night-time waking is stronger (p=0.002 or less for all comparisons).

Concerning side effects of benzodiazepines, there were no statistically significant differences between GPs and CPs for 3 of the 5 items. GPs rated craving more often and CPs believed that falls are more often under benzodiazepines. Interestingly, for 4 of the 5 studied side effects of Z-drugs CPs perceived that they occur statistically significant more often then GPs (p=0.003 or less for all comparisons). For instance, whereas 45.2% of the participating CPs answered that withdrawal effects on stopping happen often or very often/always on Z-drugs, these were only 28.3% of the GPs. No statistically significant difference between both groups was found for craving.

When comparing the overall ratio of benefits and harms of both drugs in younger and elder patients, GPs more often perceived that harms outweigh benefits in younger and older patients using benzodiazepines (Figure 1 [(Fig. 1)](#F1){ref-type="fig"}). On the other hand, no difference between GPs and CPs was found for the ratio of benefits and harms of Z-drugs for younger as well as elder patients.

Discussion
==========

Although there is no compelling evidence for clinically relevant differences in effectiveness and safety between both substance groups \[[@R3]\], \[[@R4]\], the newer Z-drugs are often prescribed instead of short-acting benzodiazepine hypnotics. A reason for this seems to be that GPs attribute Z-drugs with greater benefits and fewer side effects compared to benzodiazepines \[[@R1]\], \[[@R7]\]. The starting point of this analysis was the hypothesis that pharmacists might have a better knowledge on adverse effects of drugs. This was supported by an earlier study in which pharmacists displayed a better therapeutic knowledge of simple analgesics than GPs \[[@R11]\] but refused in another survey for opioids \[[@R12]\]. Although findings for benzodiazepines were ambiguous, for 4 of the 5 studied side effects of Z-drugs CPs perceived that they occur more often then GPs. However, when comparing attitudes of pharmacists between both substance groups, Z-drugs were rated to be safer than benzodiazepines for all 5 items (p\<0.0001 for all comparisons). The same result was found for GPs \[[@R1]\].

Interestingly, about 70% of both GPs and CPs believed that benzodiazepines as well as Z-drugs have a strong or very strong effect in terms of reduced time to get to sleep. This is contrary to current evidence derived from meta-analyses of randomized trials. The improvements in sleep latency were found to be small when compared with placebo and the non-specific placebo response is a major contributor to the effectiveness of hypnotics \[[@R14]\], \[[@R15]\]. Another interesting finding is that the overall ratio of benefits and harms of Z-drugs in elder patients was comparable to their younger counterparts or even rated more positive. This was found for both healthcare professionals and is not supported by current evidence. For persons aged 60 years or older, the benefits of hypnotics may not justify the increased risk \[[@R8]\]. This is important because prescribing of hypnotics increases with age \[[@R5]\], \[[@R6]\]. An overestimation of true effectiveness and the perception of fewer side effects of Z-drugs might lead to more frequent use.

Though a large sample of German GPs and CPs could be studied, some limitations have to be considered. The response of about one third for both surveys seems to be low and this might lead to selection bias. However, this response is quite comparable with other recently published surveys of German GPs \[[@R1]\]. Another source of bias might be social desirability when studying healthcare professionals' perceptions on psychotropic substances that have the potential to cause dependence and tolerance. It might also be that responses are related to evidence-based knowledge in some participants and to experience-based knowledge in others, which might lead to different perceptions. A further criticism refers to the fact that questions on perceptions on benefits and side effects were not divided into short-term and long-term use. However, this was also not done in the survey of British GPs conducted by Siriwardena et al. \[[@R7]\], from which items were adopted.

Conclusions
===========

It is difficult to draw unambiguous conclusions from the findings of this study. Pharmacists seem to have a somewhat more critical view on Z-drugs, especially concerning side effects. However, they also perceive more often than GPs that benefits outweigh harms in younger and older patients using benzodiazepines. Overall, both GPs as well as CPs perceived that Z-drugs were more effective and safer compared to benzodiazepines, which is not supported by current evidence. Such beliefs of healthcare professionals seem to be a barrier for the implementation of guidelines.

Notes
=====
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